Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 04, 2022 |
| Veradermics, IncMANE · Entity 1907 | Director | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 3,025,001 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Common SharesSEC Table I · non-derivative | IndirectBy John W Childs 2013 Revocable Trust | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Veradermics, Inc
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 279,117 |
Reported balance
After 2026-08-12 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 15,000 · Balance 279,117 F1: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 199,117 |
Reported balance
After 2026-08-12 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-08-12 · Sale · Disposed 80,000 · Balance 199,117 F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 194,117 |
Reported balance
After 2026-08-12 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-08-12 · Sale · Disposed 5,000 · Balance 194,117 F2: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,907,889 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,907,889 F4: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MATTRESS FIRM HOLDING CORP.
Report date September 14, 2016 · Filed September 16, 2016
Jointly reported with J.W. Childs Associates, Inc., J.W. Childs Associates, L.P., J.W. Childs Advisors III, L.P., Winter Street Opportunities Fund, L.P., JWC FUND III CO INVEST LLC, JWC Mattress Holdings, LLC
Section 16 reporting ended · disclosed 2016-09-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2016-09-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2016-09-14 · Other · Disposed 540,653 · Balance 0 F1: Represents shares directly held by Winter Street Opportunities Fund, L.P. ("WSOF"). J.W. Childs Advisors III, L.P. ("GPLP") is the general partner of WSOF. J.W. Childs Associates, L.P. ("JWC Associates LP") is the general partner of GPLP. J.W. Childs Associates, Inc. ("JWC Associates Inc.") is the general partner of JWC Associates LP. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than WSOF) disclaims pecuniary interest in the reported securities except to the extent of its economic interest. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2016-09-14 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2016-09-14 · Other · Disposed 18,787 · Balance 0 F2: Represents shares directly held by JWC Fund III Co-Invest, LLC ("Co-Invest III"). WSOF holds approximately 26% of the membership interests in Co-Invest III. GPLP is the general partner of WSOF. JWC Associates LP is the general partner of GPLP. JWC Associates Inc. is the general partner of JWC Associates LP and the manager of Co-Invest III. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than Co-Invest III) disclaims pecuniary interest in the reported securities except to the extent of his economic interest. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2016-09-14 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2016-09-14 · Other · Disposed 12,713,589 · Balance 0 F3: Represents shares directly held by JWC Mattress Holdings, LLC ("Mattress Holdings"). WSOF and Co-Invest III hold approximately 97.3% and approximately 2.7%, respectively, of the membership interests in Mattress Holdings. GPLP is the general partner of WSOF. JWC Associates LP is the general partner of GPLP. JWC Associates Inc. is the general partner of JWC Associates LP and the manager of each of Mattress Holdings and Co-Invest III. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than Mattress Holdings) disclaims pecuniary interest in the reported securities except to the extent of its economic interest. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2016-09-14 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2016-09-14 · Other · Disposed 326,251 · Balance 0 F4: Represents shares directly held by the John W. Childs 2013 Charitable Remainder Trust. Mr. Childs is the sole trustee of the John W. Childs 2013 Charitable Remainder Trust. Mr. Childs disclaims pecuniary interest in the reported securities except to the extent of his economic interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares directly held by Winter Street Opportunities Fund, L.P. ("WSOF"). J.W. Childs Advisors III, L.P. ("GPLP") is the general partner of WSOF. J.W. Childs Associates, L.P. ("JWC Associates LP") is the general partner of GPLP. J.W. Childs Associates, Inc. ("JWC Associates Inc.") is the general partner of JWC Associates LP. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than WSOF) disclaims pecuniary interest in the reported securities except to the extent of its economic interest.
F2: Represents shares directly held by JWC Fund III Co-Invest, LLC ("Co-Invest III"). WSOF holds approximately 26% of the membership interests in Co-Invest III. GPLP is the general partner of WSOF. JWC Associates LP is the general partner of GPLP. JWC Associates Inc. is the general partner of JWC Associates LP and the manager of Co-Invest III. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than Co-Invest III) disclaims pecuniary interest in the reported securities except to the extent of his economic interest.
F3: Represents shares directly held by JWC Mattress Holdings, LLC ("Mattress Holdings"). WSOF and Co-Invest III hold approximately 97.3% and approximately 2.7%, respectively, of the membership interests in Mattress Holdings. GPLP is the general partner of WSOF. JWC Associates LP is the general partner of GPLP. JWC Associates Inc. is the general partner of JWC Associates LP and the manager of each of Mattress Holdings and Co-Invest III. John W. Childs is the sole shareholder of JWC Associates Inc. Each Reporting Person (other than Mattress Holdings) disclaims pecuniary interest in the reported securities except to the extent of its economic interest.
F4: Represents shares directly held by the John W. Childs 2013 Charitable Remainder Trust. Mr. Childs is the sole trustee of the John W. Childs 2013 Charitable Remainder Trust. Mr. Childs disclaims pecuniary interest in the reported securities except to the extent of his economic interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 22:01 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon Stock | 5,000 | $108.24 | $541,200.00 |
DisclosureSEC source: 0001628280-26-057196 · wk-form4_1786744911.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 194,117 F2 · ownership.nature: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 22:01 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon Stock | 80,000 | $107.23 | $8,578,400.00 |
DisclosureSEC source: 0001628280-26-057196 · wk-form4_1786744911.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 199,117 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 22:01 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon Stock | 15,000 | $106.14 | $1,592,100.00 |
DisclosureSEC source: 0001628280-26-057196 · wk-form4_1786744911.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 279,117 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| April 28, 2026 Filed May 1, 2026 00:07 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 68,693 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001027035-26-000008 · wk-form4_1777594070.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,693 Underlying: Common Shares · 68,693 shares Expires 2036-04-28 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries C Convertible Preferred Stock · Derivative | 520,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005906 · wk-form4_1770336237.xml · derivative · entry 7 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 520,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries B Convertible Preferred Stock · Derivative | 906,862 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005906 · wk-form4_1770336237.xml · derivative · entry 6 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 906,862 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.exercise_date: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.expiration_date: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries A Convertible Preferred Stock · Derivative | 480,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005906 · wk-form4_1770336237.xml · derivative · entry 5 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 480,269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon Stock | 294,117 | $17.00 | $4,999,989.00 |
DisclosureSEC source: 0001628280-26-005906 · wk-form4_1770336237.xml · nonDerivative · entry 4 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,202,006 F2 · ownership.nature: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 520,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005906 · wk-form4_1770336237.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,907,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 906,862 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005906 · wk-form4_1770336237.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,387,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 480,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005906 · wk-form4_1770336237.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 480,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| February 05, 2026 Filed Feb 27, 2026 21:44 UTC Amendment | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon Stock | 294,117 | $17.00 | $4,999,989.00 |
DisclosureSEC source: 0001027035-26-000004 · wk-form4a_1772228643.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 294,117 F1 · shares: This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on February 5, 2026 (Original Form 4). The Original Form 4 inadvertently misstated that 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P. However, as reflected in this amendment, 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through the John W. Childs 2013 Revocable Trust, and no shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P. F1 · balance_after: This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on February 5, 2026 (Original Form 4). The Original Form 4 inadvertently misstated that 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P. However, as reflected in this amendment, 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through the John W. Childs 2013 Revocable Trust, and no shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P. F1 · ownership.nature: This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on February 5, 2026 (Original Form 4). The Original Form 4 inadvertently misstated that 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P. However, as reflected in this amendment, 294,117 shares of Common Stock were indirectly acquired by the Reporting Person through the John W. Childs 2013 Revocable Trust, and no shares of Common Stock were indirectly acquired by the Reporting Person through J.W. Childs Associates (FL), L.P. F2 · ownership.nature: Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | GrantStock Option (Right to Buy) · Derivative | 51,525 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005906 · wk-form4_1770336237.xml · derivative · entry 8 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,525 Underlying: Common Stock · 51,525 shares Expires 2036-02-03 F5 · derivative.exercise_date: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 12:30 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 3,333,333 | $7.50 | $24,999,997.50 |
DisclosureSEC source: 0001027035-25-000004 · wk-form4_1763382643.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 5,653,904 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| May 05, 2025 Filed May 7, 2025 21:12 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 31,716 | $0.00 Strike: $22.62 | $0.00 |
DisclosureSEC source: 0001935979-25-000042 · wk-form4_1746652349.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716 Underlying: Common Shares · 31,716 shares Expires 2035-05-05 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 12:01 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 900 | $30.73 | $27,653.49 |
DisclosureSEC source: 0001935979-25-000018 · wk-form4_1741176105.xml · nonDerivative · entry 4 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 1994 Charitable Remainder Trust Disclosed balance after: 25,291 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.54 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 12:01 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 3,400 | $30.73 | $104,468.74 |
DisclosureSEC source: 0001935979-25-000018 · wk-form4_1741176105.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2013 Charitable Remainder Trust Disclosed balance after: 76,570 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.54 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 12:01 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 3,400 | $30.73 | $104,468.74 |
DisclosureSEC source: 0001935979-25-000018 · wk-form4_1741176105.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2007 Charitable Remainder Trust Disclosed balance after: 24,452 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.54 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 12:01 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 25,000 | $30.39 | $759,647.50 |
DisclosureSEC source: 0001935979-25-000018 · wk-form4_1741176105.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,320,571 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.17 - $30.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 04, 2025 Filed Mar 9, 2026 22:12 UTC Amendment | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 28,400 | $30.43 | $864,115.44 |
DisclosureSEC source: 0001027035-26-000006 · wk-form4a_1773094322.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,323,971 F1 · shares: This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on March 5, 2025 (the "Original Form 4"). The Original Form 4 inadvertently misstated that 3,400 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and 25,000 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 28,400 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust, and no Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.17 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.17 - $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 12:00 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 29,000 | $35.94 | $1,042,393.40 |
DisclosureSEC source: 0001935979-24-000088 · wk-form4_1735646406.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,368,741 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.57 - $36.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 11:01 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 21,052 | $47.50 | $999,970.00 |
DisclosureSEC source: 0001935979-24-000078 · wk-form4_1727953276.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2007 Charitable Remainder Trust Disclosed balance after: 21,052 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 12:56 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 28,400 | $35.67 | $1,012,982.56 |
DisclosureSEC source: 0001562180-24-005805 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,339,741 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.485 - $35.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 30, 2024 Filed May 31, 2024 13:04 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 28,000 | $35.58 | $996,240.00 |
DisclosureSEC source: 0001562180-24-004529 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,311,341 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.29 - $35.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 13, 2024 Filed May 14, 2024 11:30 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 28,500 | $35.17 | $1,002,470.40 |
DisclosureSEC source: 0001562180-24-004011 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,283,341 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 - $35.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003750 · primarydocument.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 73,170 | $41.00 | $2,999,970.00 |
DisclosureSEC source: 0001562180-24-003494 · primarydocument.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,254,841 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 97,560 | $41.00 | $3,999,960.00 |
DisclosureSEC source: 0001562180-24-003494 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2021 B-H Charitable Remainder Trust Disclosed balance after: 4,096,512 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 24,391 | $41.00 | $1,000,031.00 |
DisclosureSEC source: 0001562180-24-003494 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 1994 Charitable Remainder Trust Disclosed balance after: 24,391 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 22, 2024 Filed Mar 5, 2025 11:59 UTC Amendment | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 73,170 | $41.00 | $2,999,970.00 |
DisclosureSEC source: 0001935979-25-000017 · wk-form4a_1741175981.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2013 Charitable Remainder Trust Disclosed balance after: 73,170 F1 · shares: Represents common shares acquired in an underwritten public offering. F2 · shares: This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on April 23, 2024 (the "Original Form 4"). The Original Form 4 inadvertently misstated that 73,170 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 73,170 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and no Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. F2 · balance_after: This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on April 23, 2024 (the "Original Form 4"). The Original Form 4 inadvertently misstated that 73,170 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 73,170 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and no Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:21 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 2,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003337 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,181,671 F1 · kind: Pursuant to a merger transaction, consummated on January 8, 2024, 48,505 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 2,091 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to a merger transaction, consummated on January 8, 2024, 48,505 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 2,091 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 23:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 19,412 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-002510 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,179,580 F1 · kind: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. Read SEC document |
| January 08, 2024 Filed Jan 11, 2024 02:11 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 48,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-000427 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,160,168 F1 · kind: Pursuant to a merger transaction, consummated on January 8, 2024, common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to a merger transaction, consummated on January 8, 2024, common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 23:07 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 136,545 | $22.00 | $3,003,990.00 |
DisclosureSEC source: 0001562180-23-007253 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,111,663 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 23:07 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 318,000 | $22.00 | $6,996,000.00 |
DisclosureSEC source: 0001562180-23-007253 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2021 B-H Charitable Remainder Trust Disclosed balance after: 3,998,952 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 12:56 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 50,000 | $18.44 | $922,180.00 |
DisclosureSEC source: 0001562180-23-006632 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 1,975,118 Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 11:29 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 100,000 | $19.78 | $1,978,430.00 |
DisclosureSEC source: 0001562180-23-006204 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 1,925,118 Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 52,906 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001562180-23-003942 · primarydocument.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,906 Underlying: Common Shares · 52,906 shares Expires 2033-05-02 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| October 25, 2022 Filed Oct 26, 2022 22:22 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 3,900,000 | $10.50 | $40,950,000.00 |
DisclosureSEC source: 0001562180-22-007334 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,691,251 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| October 25, 2022 Filed Mar 22, 2023 22:07 UTC Amendment | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 1,328,867 | $10.50 | $13,953,103.50 |
DisclosureSEC source: 0001562180-23-003045 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 1,825,118 F1 · shares: Represents Common Shares acquired in an underwritten public offering. F2 · balance_after: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 26, 2022 (the "Original Form 4") and to correct the total amount of Common Shares beneficially owned by the Reporting Person reported in the Original Form 4. The Original Form 4 inadvertently misstated the amount of Common Shares beneficially owned by the Reporting Person; however, as reflected in this amendment, the total amount of Common Shares beneficially owned by the Reporting Person is 5,506,070 Common Shares. In addition, the Original Form 4 inadvertently misstated that 5,691,251 Common Shares were directly held by the Reporting Person. However, as reflected in this amendment, no Common Shares were directly held by the Reporting Person. Rather, 1,825,118 Common Shares were indirectly held by the Reporting Person through the John W Childs 2013 Revocable Trust and 3,680,952 Common Shares were indirectly held by the Reporting Person in the 2021 B-H Charitable Remainder Trust. F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 26, 2022 (the "Original Form 4") and to correct the total amount of Common Shares beneficially owned by the Reporting Person reported in the Original Form 4. The Original Form 4 inadvertently misstated the amount of Common Shares beneficially owned by the Reporting Person; however, as reflected in this amendment, the total amount of Common Shares beneficially owned by the Reporting Person is 5,506,070 Common Shares. In addition, the Original Form 4 inadvertently misstated that 5,691,251 Common Shares were directly held by the Reporting Person. However, as reflected in this amendment, no Common Shares were directly held by the Reporting Person. Rather, 1,825,118 Common Shares were indirectly held by the Reporting Person through the John W Childs 2013 Revocable Trust and 3,680,952 Common Shares were indirectly held by the Reporting Person in the 2021 B-H Charitable Remainder Trust. Read SEC document |
| October 25, 2022 Filed Mar 22, 2023 22:07 UTC Amendment | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 2,380,952 | $10.50 | $24,999,996.00 |
DisclosureSEC source: 0001562180-23-003045 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2021 B-H Charitable Remainder Trust Disclosed balance after: 3,680,952 F1 · shares: Represents Common Shares acquired in an underwritten public offering. F2 · balance_after: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 26, 2022 (the "Original Form 4") and to correct the total amount of Common Shares beneficially owned by the Reporting Person reported in the Original Form 4. The Original Form 4 inadvertently misstated the amount of Common Shares beneficially owned by the Reporting Person; however, as reflected in this amendment, the total amount of Common Shares beneficially owned by the Reporting Person is 5,506,070 Common Shares. In addition, the Original Form 4 inadvertently misstated that 5,691,251 Common Shares were directly held by the Reporting Person. However, as reflected in this amendment, no Common Shares were directly held by the Reporting Person. Rather, 1,825,118 Common Shares were indirectly held by the Reporting Person through the John W Childs 2013 Revocable Trust and 3,680,952 Common Shares were indirectly held by the Reporting Person in the 2021 B-H Charitable Remainder Trust. F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 26, 2022 (the "Original Form 4") and to correct the total amount of Common Shares beneficially owned by the Reporting Person reported in the Original Form 4. The Original Form 4 inadvertently misstated the amount of Common Shares beneficially owned by the Reporting Person; however, as reflected in this amendment, the total amount of Common Shares beneficially owned by the Reporting Person is 5,506,070 Common Shares. In addition, the Original Form 4 inadvertently misstated that 5,691,251 Common Shares were directly held by the Reporting Person. However, as reflected in this amendment, no Common Shares were directly held by the Reporting Person. Rather, 1,825,118 Common Shares were indirectly held by the Reporting Person through the John W Childs 2013 Revocable Trust and 3,680,952 Common Shares were indirectly held by the Reporting Person in the 2021 B-H Charitable Remainder Trust. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 01:44 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 32,841 | $9.70 | $318,403.35 |
DisclosureSEC source: 0001562180-22-007104 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791,251 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.46 - $9.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 01:44 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 241,300 | $8.88 | $2,142,768.13 |
DisclosureSEC source: 0001562180-22-007104 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,758,410 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 - $9.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 00:29 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 11,996 | Not disclosed Strike: $70.17 | Not disclosed |
DisclosureSEC source: 0001562180-22-006964 · primarydocument.xml · derivative · entry 4 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 11,996 shares Expires 2031-05-05 F3 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 00:29 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 8,239 | Not disclosed Strike: $95.33 | Not disclosed |
DisclosureSEC source: 0001562180-22-006964 · primarydocument.xml · derivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,239 shares Expires 2032-04-28 F3 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F3 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 00:29 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerCommon Shares | 10,000 | $148.50 | $1,485,000.00 |
DisclosureSEC source: 0001562180-22-006964 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 00:29 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerCommon Shares | 3,025,001 | $148.50 | $449,212,648.50 |
DisclosureSEC source: 0001562180-22-006964 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:35 UTC Amendment | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007102 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 5,000 F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Shares acquired were indirectly held by the Reporting Person in the John W. Childs 2013 Revocable Trust. There were no other changes made to the information in the Original Filing. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:35 UTC Amendment | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 1,512,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007102 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517,110 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Shares acquired were indirectly held by the Reporting Person in the John W. Childs 2013 Revocable Trust. There were no other changes made to the information in the Original Filing. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007078 · primarydocument.xml · derivative · entry 9 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F4 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.